Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
|ClinicalTrials.gov Identifier: NCT00999843|
Recruitment Status : Unknown
Verified October 2009 by Fudan University.
Recruitment status was: Recruiting
First Posted : October 22, 2009
Last Update Posted : October 22, 2009
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||October 2010|
|Estimated Study Completion Date :||October 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Zhao JD, Liu J, Ren ZG, Gu K, Zhou ZH, Li WT, Chen Z, Xu ZY, Liu LM, Jiang GL. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol. 2010 Feb 12;5:12. doi: 10.1186/1748-717X-5-12.